桂林莱茵生物科技股份有限公司 二、股东股份累计质押情况 证券代码：002166 证券简称：莱茵生物 公告编号：2025-041 桂林莱茵生物科技股份有限公司 关于控股股东部分股份质押延期购回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到控股 股东、实际控制人秦本军先生的通知，获悉秦本军先生将其质押给国泰海通证券 股份有限公司（以下简称"国泰海通"）的股份办理了延期购回业务，具体事项 如下： | | 是否为控 股股东或 | 本次延 期购回 | 占其所 | 占公司 | | 是否 | 质押 | | 原质 | 延期 购回 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | | 持股份 | 总股本 | 是否 | 为补 | | | | | 质权 | 质押 | | | 第一大股 | 股份数 | | | | | 起始 | | 押到 | 后质 | | | | 名称 | 东 ...

Group 1 - The core point of the announcement is that Qin Benjun, the controlling shareholder of Guilin Rhine Biotechnology Co., Ltd., has extended the repurchase of pledged shares to Guohai Securities Co., Ltd. [1] - The total number of shares pledged by Qin Benjun is 10,070,000, which accounts for 37.11% of his holdings and 13.58% of the company's total share capital [1][2] - As of the announcement date, Qin Benjun's pledged shares amount to 27,138,960, representing 23.43% of his total holdings, with 7,668,880 shares (36.59%) being pledged [2] Group 2 - The announcement details that 6,593,440 shares are due for repayment within the next six months, which is 24.30% of the pledged shares and 8.89% of the company's total share capital [2] - A total of 16,663,440 shares are due within the next year, representing 61.40% of the pledged shares and 22.47% of the company's total share capital [2] - The company confirms that Qin Benjun has a good credit status and sufficient funds to repay the financing, with repayment sources being self-raised funds [2]

证券代码：002166 证券简称：莱茵生物 公告编号：2025-040 桂林莱茵生物科技股份有限公司 桂林莱茵生物科技股份有限公司 关于控股股东部分股份质押延期购回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到控股 股东、实际控制人秦本军先生的通知，获悉秦本军先生将其质押给国海证券股份 有限公司（以下简称"国海证券"）的股份办理了延期购回，具体事项如下： 二、股东股份累计质押情况 截至公告披露日，上述股东所持质押股份情况如下： | | | | | 合计占 | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 持股 | 累计被质 | 其所持 | 占公司 | 已质押股 | | 未质押 | 占未 | | 股东 | 持股数量 | | | | 总股本 | 份限售和 | 占已质 | 股份限 | 质押 | | 名称 | （万股） | 比例 | 押股份数 | 股份比 | ...

Core Insights - The article discusses recent developments in the nutrition and health industry, highlighting regulatory changes, new product approvals, and market trends that could impact investment opportunities [2][3][4][5][6]. Regulatory Developments - The State Administration for Market Regulation issued a guideline clarifying the definition of commercial advertising under the Advertising Law, addressing ongoing disputes in advertising enforcement [2]. - The National Health Commission approved D-alloheptulose and four other substances as new food raw materials, indicating a push for innovation in the nutrition sector [3]. - The market regulator released multiple responses to proposals regarding health food regulations, signaling a focus on traditional Chinese medicine formulations as a potential growth area [4]. Market Trends and Investment Opportunities - Yangtuo Technology Inc. submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds for market expansion and supply chain optimization, reflecting growing investor interest in the nutrition and health sector [5]. - A report on 68 nutrition and health companies showed an average market value increase of 20% in the first half of the year, driven by rising consumer health awareness and demand for nutritional products [6]. Company Performance - New Hope Liuhe (002001) projected a net profit of 3.3 billion to 3.75 billion yuan for the first half of 2025, representing a year-on-year growth of 50% to 70% [12]. - Brother Technology (002562) expects a net profit of 60 million to 75 million yuan for the same period, marking an increase of 325% to 431% compared to the previous year [13]. New Product Launches - Guangji Pharmaceutical (000952) received a notice of administrative penalty for information disclosure violations, indicating regulatory scrutiny in the sector [14]. - TCM brand Tongrentang launched its first OTC glucosamine product, expanding its product line in the bone and joint health category [14].

Core Insights - The demand for grape seed health products is increasing due to rising living standards and health awareness among consumers [1][16] - The market size of grape seed health products in China is projected to grow from 5 billion yuan in 2019 to 9 billion yuan by 2024, with a compound annual growth rate of 12% [1][16] - Technological advancements in extraction efficiency and purity are supporting the growth of the grape seed health product market [1][16] Industry Overview - Grape seed health products are derived from grape seeds and contain beneficial components such as vitamins, minerals, amino acids, and antioxidants, offering various health benefits [3][10] - The industry can be categorized by product form (tablets, capsules, liquid), efficacy (antioxidant, anti-aging), and usage scenarios (daily health, beauty, sports nutrition) [5][10] Market Dynamics - The grape seed health product market is experiencing rapid expansion due to the growth of e-commerce and diversified marketing channels [1][16] - The increase in grape production in China, from 13.16 million tons in 2015 to 16.17 million tons in 2023, is expected to provide ample raw materials for grape seed health products [12][14] Regulatory Environment - Recent policies in China aim to promote the integration of the food industry with health and wellness sectors, enhancing the market for functional foods and health products [6][9] Competitive Landscape - Major players in the grape seed health product market include well-known domestic brands such as汤臣倍健 (Tongrentang), 康恩贝 (Kang En Bei), and 九芝堂 (Jiu Zhi Tang), as well as international brands like Nature's Way and NOW Foods [18][19] - Companies are enhancing their competitiveness through improved production technologies and brand marketing strategies [18][19] Consumer Trends - There is a notable increase in consumer demand for high-quality grape seed health products, particularly among women and young adults aged 18 to 35, who represent 83.7% of the health supplement market [24][25] - Consumers are increasingly focused on product quality, efficacy, and safety, necessitating continuous improvement in product formulations [24][25] Future Outlook - The industry is expected to benefit from technological advancements that enhance product absorption and bioavailability [25][26] - The trend of online and offline integration in sales channels is becoming crucial for market growth, providing consumers with a more convenient shopping experience [26][27] - International expansion is a growing trend, with Chinese companies leveraging their resources and technology to compete in global markets [27]

Core Insights - The mulberry leaf extract industry in China is rapidly developing due to the increasing demand for natural plant extracts and the medicinal and health benefits of mulberry leaves [1][6][22] - China is one of the richest countries in mulberry resources, with a complete industrial chain extending from mulberry cultivation to high-value extracts [1][4] - The market size for mulberry leaf extract is projected to grow from 199.17 million yuan in 2024 to 217.65 million yuan in 2025, with an industry output value expected to reach 300.65 million yuan [1][6] Industry Definition and Classification - Mulberry leaves (Folium Mori) are the dried leaves of the mulberry plant, known for their medicinal properties, including clearing lung heat and improving vision [2] - The main functional components of mulberry leaf extract include polyphenols, flavonoids, alkaloids, and polysaccharides, which are associated with antioxidant capabilities [2][4] Current Development Status - The mulberry leaf extract industry has seen a steady increase in demand due to rising health awareness and preference for natural products, leading to market expansion [4][6] - The production capacity of mulberry leaf extract in China is expected to grow from 834 tons in 2024 to 892 tons in 2025, with production increasing from 563 tons to 598.4 tons [4][6] Industry Chain - The upstream of the mulberry leaf extract industry includes mulberry cultivation and extraction production equipment, with raw material costs accounting for over 90% of the total cost [8][10] - The downstream applications of mulberry leaf extract include pharmaceuticals, cosmetics, health products, and food and beverages [8] Industry Development History - The plant extraction industry in China has a long history, with significant advancements in extraction methods since the 1990s, leading to a golden development period in the 21st century [15] Competitive Landscape - The mulberry leaf extract industry exhibits a clear technological stratification, with leading companies using proprietary technologies to dominate the high-end market [17][19] - Major companies in the industry include Hunan Xier Natural Pharmaceutical Co., Ltd., Hunan Huakang Biotechnology Co., Ltd., and Guilin Rhine Biotechnology Co., Ltd. [17][19] Industry Development Trends - The demand for mulberry leaf extract is expected to grow as consumers increasingly seek natural and healthy products, particularly in the fields of medicine, food, and health supplements [22]

桂林莱茵生物科技股份有 限公司 证券代码：002166 证券简称：莱茵生 物 公告编号：2025-039 桂林莱茵生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到控股 股东、实际控制人秦本军先生的通知，获悉秦本军先生将其质押给国泰海通证券 股份有限公司（以下简称"国泰海通"）的股份办理了解除质押，具体事项如下： 一、本次解除质押的基本情况 桂林莱茵生物科技股份有限公司 持股份比例、占公司总股本比例以及对应融资余额如下表所示： 到期的质押股份累计 占所持股份 占公司总股本 对应融资余额 时段 数量（万股） 比例 比例 （万元） 未来半年内到期 16,663.44 61.40% 22.47% 22,307.6107 未来一年内到期 16,663.44 61.40% 22.47% 22,307.6107 利益的情形。 份不存在平仓风险或被强制平仓的情形。其股份质押事项不会导致公司实际控制 权发生变更，不会对公司生产经营和公司治理产生影响，且不存在重大资产重组 等业绩补偿义务。若出现平 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-039 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到控股 股东、实际控制人秦本军先生的通知，获悉秦本军先生将其质押给国泰海通证券 股份有限公司（以下简称"国泰海通"）的股份办理了解除质押，具体事项如下： 二、股东股份累计质押情况 截至公告披露日，上述股东所持质押股份情况如下： | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 合计占 | 占公司 | | | 未质押 | | | | | 持股 | 累计被质 | | | 已质押股 | 占已质 | 股份限 | 占未 | | 股东 | 持股数量 | | | 其所持 | 总股本 | 份限售和 | | | 质押 | | 名称 | （万股） | 比例 | 押股份数 | 股份比 | 比例 | | 押股份 | 售和冻 | | | | | （%） | 量（万股） | | | 冻结、标记 | | | 股份 ...

证券代码：002166 证券简称：莱茵生物 公告编号：2025-038 桂林莱茵生物科技股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外担保进展情况概述 （一）本次对外担保情况 近日，桂林莱茵生物科技股份有限公司（以下简称"公司"）控股子公司成 都华高生物制品有限公司（以下简称"华高生物"）向成都银行股份有限公司蒲 江支行申请了人民币1,000万元最高额融资额度，该债务由成都金控融资担保有 限公司（以下简称"成都金控担保"）提供连带责任保证担保，担保金额为1,000 万元人民币。公司与成都金控担保签订了《最高额保证反担保合同》，就公司控 股子公司华高生物向成都银行股份有限公司蒲江支行申请最高额融资事项，向成 都金控担保提供主债权本金最高额1,000万元的连带责任保证反担保。该笔担保 完成后，公司就控股子公司华高生物向成都银行股份有限公司蒲江支行申请的贷 款提供的连带责任保证反担保总额为1,500万元。 桂林莱茵生物科技股份有限公司 （二）对外担保审议情况 公司于2025年3月26日召开第七届董事会第四次 ...

Group 1 - The event organized by Dongfang Securities aimed to enhance investor protection and transparency of listed companies, aligning with the new "National Nine Articles" policy [1] - The event featured a visit to the Guilin production base of Lain Bio, showcasing its advanced technologies and digital management processes in the plant extraction industry [1] - Lain Bio's production line for enzyme-synthesized RebM2 is the first of its kind globally, offering significant advantages over traditional methods, including lower energy consumption and higher raw material utilization [1] Group 2 - The company expects to produce over 1,000 tons of enzyme-synthesized products annually, with an estimated annual output value exceeding 1 billion yuan [1] - During the investor communication session, Lain Bio's secretary emphasized the importance of ongoing dialogue between the company and its investors [3] - Investors expressed increased confidence in Lain Bio's development after witnessing its operations firsthand, highlighting the event's role in enhancing understanding of the plant extraction industry's technological and market potential [3]